Use of a real-world synthetic control arm for direct comparison of lisocabtagene maraleucel and conventional therapy in relapsed/refractory large B-cell lymphoma
(2023)
Journal Article
Van Le, H., Van Naarden Braun, K., Nowakowski, G. S., Sermer, D., Radford, J., Townsend, W., …Hasskarl, J. (2023). Use of a real-world synthetic control arm for direct comparison of lisocabtagene maraleucel and conventional therapy in relapsed/refractory large B-cell lymphoma. Leukemia & Lymphoma, 64(3), 573-585. https://doi.org/10.1080/10428194.2022.2160200
This study used a real-world population as a synthetic comparator for the single-arm TRANSCEND NHL 001 study (TRANSCEND; NCT02631044) to evaluate the efficacy of lisocabtagene maraleucel (liso-cel) compared with conventional (noncellular) therapies i... Read More about Use of a real-world synthetic control arm for direct comparison of lisocabtagene maraleucel and conventional therapy in relapsed/refractory large B-cell lymphoma.